Citizens are fighting back! Here is the original post regarding the new New York forced vaccine law opening the door for Child Protective Services to take children from parents: https://voat.co/v/pizzagate/3308482
There is now video evidence of corrupt proceedings in the original Committee vote to get the bill to the floor of the Assembly with a vote and bill signing IN ONE DAY.
VIDEO EVIDENCE:
"FBI - PLEASE INVESTIGATE NY STATE’S POTENTALLY CORRUPT VOTE TO REPEAL A RELIGIOUS FREEDOM" (religious vaccine exemption)
https://vimeo.com/345081341
view the rest of the comments →
ADaniels ago
Funny, how if you are already vaxxed, you should be immune from the disease and not be worried if other children havn't been vaxxed yet..... Clearly there are other motivations here.....
poly ago
Obligatory “muh immunocompromised child” comment
Whenever you hear this bs, just know that they are immunocompromised because of vaccines
InyourfaceNancyGrace ago
This is so laughably backwards it's hard to believe you're saying it unironically... but I've really come to expect it in the anti-vax world.
Immunocompromised kids don't get vaccines BECAUSE THEY'RE IMMUNOCOMPROMISED so introducing a weakened or dead version of the bug would likely kill them! Alternatively - they have cancer and have undergone radiation therapy. Or are we claiming vaccines cause cancer now too?
I don't think I've read of a single instance where vaccines actually compromised someone's immune function. Negligible effects, yes, boosted, yes, but compromised? I'm pretty sure that's never happened.
But when you hold such a strong belief despite the mountains of evidence contrary to that belief, it becomes much more evident as to why you say such stupid things.
septimasexta ago
"Immunocompromised kids don't get vaccines..." WELL, YES THEY DO.
"Vaccination for people who are immunocompromised People who are immunocompromised may need extra doses of some vaccines to optimise protection. Some vaccines are contraindicated in these people." https://immunisationhandbook.health.gov.au/vaccination-for-special-risk-groups/vaccination-for-people-who-are-immunocompromised
"Vaccines Safe for Use in Immunocompromised Persons" https://primaryimmune.org/wp-content/uploads/2011/04/Immunization-Of-The-Immunocompromised-Host.pdf
https://www.childrensimmunization.org/uploads/VaccinationsandImmunocompromisedchildren-CCIChandout.pdf
InyourfaceNancyGrace ago
Okay, so which is it? Vaccines caused them to be immunocompromised, or they're immunocompromised so they need more vaccines?
From your first source. Generally you don't vax immunocompromised kids, or you already know they're immunocompromised before the vaccines are administered, so you choose the one that is safe for immunocompromised individuals (e.g. an antigen-only, or even polypeptide capsid fragment).
septimasexta ago
Confusing, isn't it? Pharma's expertise on " the immunocompromised" is about as good as their "liability free" vaccine safety studies, where the placebo IS ANOTHER VACCINE! LOL! Unfortunately for Wellcome controlled GSK, the new experimental HeplisavB safety trials revealed a 70-90% for Glaxo's EngerixB. Well below the FDA standard of 95%. OOOOOPS! That's what you get when you use a VACCINE for a PLACEBO. LOL!
InyourfaceNancyGrace ago
No, it's not. Vaccines don't cause people to be immunocompromised - it is a preexisting condition that tells the doctor not to administer live-virus vaccines.
And your example of the HepB vax failing safety trials is just evidence that the system is working, is it not?
septimasexta ago
"Vaccines don't cause people to be immunocompromised - it is a preexisting condition that tells the doctor not to administer live-virus vaccines." This is a research site. Making assertions won't do.
"And your example of the HepB vax failing safety trials is just evidence that the system is working"
EngerixB was not the subject of the safety trial, but HeplisavB. HeplisavB was fast-tracked through approval when Merck suddenly quit manufacturing its HepB vax in 2017. It is now in use for ages 18 and up. The CDC is currently substituting EngerixB for the "birth dose" to replace Merck's dwindling supply, which won't be replaced until after 2019 according to the latest CDC report.. Could this lead to fraud lawsuits?
Plotkin was on the Science Board of the new hepatitis B vaccine with novel adjuvant 1018 ISS, Heplisav-B vaccine (Dynavax Technologies) and stepped down around the time it received ACIP and CDC recommendations (last 2 steps to get on the CDC Childhood Recommended Vaccines list)
"Press Release Mar 2, 2018 Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies Dr. Plotkin Will Continue as Scientific Advisor BERKELEY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (“Dynavax”) (NASDAQ:DVAX) announced today that Stanley A. Plotkin, M.D. has indicated his intention to step down from the Board of Directors (“Board”) effective from the 2018 Annual Shareholder Meeting on May 31, 2018.
“I am delighted that HEPLISAV-B has been launched and recommended by the ACIP,” Dr. Plotkin said. “When I originally joined the Dynavax Board many years ago it was because I knew that new adjuvants were needed to enhance the efficacy of vaccines. Now that licensure has been achieved, and in view of my desire to reduce my travel and wider commitments, I have made the decision to resign from the Board."
"About Dynavax Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B, a hepatitis B vaccine for adults, is approved in the United States." http://investors.dynavax.com/news-releases/news-release-details/stanley-plotkin-md-steps-down-board-dynavax-technologies
TIMELINE:
December 1987 Merck's RecombivaxHB patent
"Granted Sept. 6 to the inventors of the vaccine at the University of California, San Francisco and at the University of Washington. Patent covers the hepatitis B surface antigen produced from genetically engineered yeast and the Recombivax HB vaccine. In December 1987, Biogen received a patent covering the manufacture of "all hepatitis B surface and core antigens produced by genetic engineering." Biogen's technology is licensed to SmithKline ("The Pink Sheet" April 11, T&G-4). Merck maintains that any recombinant vaccine for hepatitis B produced through genetically engineered yeast falls under the claims of its patent." https://pink.pharmaintelligence.informa.com/PS014273/Mercks-Recombivax-HB-patent
June 7-8, 2000 "Scientific Review of Vaccine Safety Datalink Information, Simpsonwood Retreat Center, Norcross, GA" https://www.safeminds.org/wp-content/uploads/2014/03/simpsonwood-transcript-scientific-review-of-vaccine-safety-datalink-information.pdf SEE PAGE 4 OF THIS DOCUMENT. I believe the doctor referred to in this MARCH 1 2017 DOJ News release is the same: "EMORY DOCTOR GOES TO PRISON FOR DOWNLOADING THOUSANDS OF IMAGES OF CHILD PORNOGRAPHY" https://www.justice.gov/usao-ndga/pr/emory-doctor-goes-prison-downloading-thousands-images-child-pornography
"The din refused to fade and became shriller still when a freedom of information act petition by Congressman David Weldon exposed the minutes of a high profile meeting of 51 officials belonging to the CDC, vaccine manufacturers, and highly placed government officials who had met in Simpsonwood, Northcross Georgia, USA on 7th – 8th June 2000 to discuss two CDC studies that found undeniable association between mercury containing vaccines and autism. The relative risk found in both the studies was 7.62[42]; any figure above 1 being a sure indication.[43] CDC correspondence between the author Thomas Verstraeten and top notch scientists revealed he had manipulated the data at his level from a RR of 11.35 and unable to do so any further sent an SOS for help, "The association will not go away." Consequently the meeting was held where the guests decided to bury the association even as a member conceded his grandchild would not receive vaccines, another expressed concerns over targets to be met, while a third highlighted a similar role of the vaccine adjuvant aluminium which he felt had equally disastrous consequences. All of them agreed that these results should not reach the public.[44]" http://www.greenmedinfo.com/blog/anti-vaccination-pro-science-pro-health-anti-industry
August 27, 2010
Qui tam action filed against Merck for "...Merck's efforts for more than a decade to defraud the United States with respect to the efficacy of Merck's mumps vaccine." (FDA requires 95%) http://probeinternational.org/library/wp-content/uploads/2014/09/chatom-v-merck.pdf https://www.naturalnews.com/gallery/documents/Merck-False-Claims-Act.pdf
June 2015: " Whistleblower attorney accuses Merck of stonewalling by withholding information and files a motion to compel Merck to comply." https://ahrp.org/former-merck-scientists-sue-merck-alleging-mmr-vaccine-efficacy-fraud/
June 27, 2017 Merck claims "malware attack."
Up until this time, Merck's Recombivax HB was used exclusively in U.S.A since 1987 when it was introduced as the FIRST recombinant vaccine. The 1986 Vaccine Injury law allowed Big Pharma vaccine liability protection by the Federal Government. "Congress calls on Merck's Frazier to report on how much havoc malware attack wreaked on manufacturing by Eric Palmer | Sep 22, 2017 " https://www.fiercepharma.com/pharma/congress-calls-merck-ceo-frazier-to-report-extent-manufacturing-interruptions-from-petya https://www.courthousenews.com/wp-content/uploads/2017/09/Letter-to-Merck.pdf
July 2017 "Merck first announced a shortage in July 2017 citing demand and manufacturing process updates. It has pushed back its predicted availability several times and plans to allocate its supply to the CDC." https://www.aappublications.org/news/2018/11/13/hepbshortage111318 (Wellcome) GLAXO SMITH KLINE EngerixB made available for "birth dose" as a Merck substitute.
July 28, 2017
"Vaccines and Related Biological Products Advisory Committee Meeting: FDA Briefing Document: Heplisav-B (Hepatitis B Vaccine Recombinant and 1018 ISS Adjuvant: Applicant: Dynavax Technologies Corp." https://www.fda.gov/media/106641/download
February 21, 2018 "In February 2018, the ACIP recommended Heplisav-B be used in patients ≥18 years of age for vaccination against hepatitis B virus." https://www.clinicaladvisor.com/home/topics/hepatology-information-center/cdc-recommendations-on-the-use-of-heplisav-b-published/ https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a5.htm
LOOK AT THE EFFICACY RATES: "The ACIP Hepatitis Vaccines Work Group conducted a systematic review of the evidence, including data from four randomized controlled trials assessing prevention of HBV infection and six randomized controlled trials assessing adverse events in adults. Seroprotective antibody to hepatitis B surface antigen (anti-HBs) levels were achieved in 90.0%–100.0% of subjects receiving HepB-CpG (Dynavax Technologies Corporation), compared with 70.5%–90.2% of subjects receiving Engerix-B (GlaxoSmithKline Biologicals)." Engerix-B is currently being used for the HepB birth dose to replace Merck's HepB vaccine. HeplisavB and its novel adjuvant has a FDA approved average 95% rate but can only be used for 18 and up. https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a5.htm
November 13, 2018 "Merck HepB vaccine shortage to continue into 2019"
"Merck first announced a shortage in July 2017 citing demand and manufacturing process updates. It has pushed back its predicted availability several times and plans to allocate its supply to the CDC." https://www.aappublications.org/news/2018/11/13/hepbshortage111318
February 15, 2019 "Merck HepB vaccine shortage extended through 2019"
"GlaxoSmithKline (GSK) has an adequate supply of hepatitis B vaccine to make up for the shortage, according to the Centers for Disease Control and Prevention (CDC). The company produces single-component Engerix-B and combination vaccine Pediarix. Merck first announced a shortage in July 2017 citing demand and manufacturing process updates. It has pushed back its predicted availability several times and plans to allocate its supply to the CDC." https://www.aappublications.org/news/2019/02/15/hepbvaccineshortage021519 November 13, 2018 "Merck HepB vaccine shortage to continue into 2019"
"Merck first announced a shortage in July 2017 citing demand and manufacturing process updates. It has pushed back its predicted availability several times and plans to allocate its supply to the CDC." https://www.aappublications.org/news/2018/11/13/hepbshortage111318
February 15, 2019 "Merck HepB vaccine shortage extended through 2019"
"GlaxoSmithKline (GSK) has an adequate supply of hepatitis B vaccine to make up for the shortage, according to the Centers for Disease Control and Prevention (CDC). The company produces single-component Engerix-B and combination vaccine Pediarix. Merck first announced a shortage in July 2017 citing demand and manufacturing process updates. It has pushed back its predicted availability several times and plans to allocate its supply to the CDC." https://www.aappublications.org/news/2019/02/15/hepbvaccineshortage021519
septimasexta ago
Since HepB is sexually transmitted and is mainly a problem in third world countries, the main benefactors of the "birth dose" would be pedophiles- just my opinion. Remember, Stanley Plotkin was on boards of both Merck and Dynavax. While the CDC says that the remaining Merck HepB vax will be mixed in with the GSK Dynavax ONLY FOR THE BIRTH DOSE, conveniently, Merck has NO stock for the 18 and up adults. Enter the "just in time" approved HeplisavB vaccine with a NEVER BEFORE COMMERCIALLY USED non-aluminum 1018 ISS adjuvant (shepherded through ACIP by Plotkin) to be used (GSK product also available) for 18 and up ADULTS. The new adjuvant affects the "Toll-like receptor-9" which theoretically can trigger an autoimmune response.
According to "Vaccines and Related Biological Products Advisory Committee Meeting: FDA Briefing Document: Heplisav-B (Hepatitis B Vaccine Recombinant and 1018 ISS Adjuvant: Applicant: Dynavax Technologies Corp." https://www.fda.gov/media/106641/download
on p. 10 "Non-clinical investigations of the potential for CpGs or Heplisav to induce autoimmunity have been suboptimal given the lack of an appropriate mouse or well-characterized NHP models of human autoimmunity."
septimasexta ago
70%-90% efficacy.